4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
4d Pharma PLC (AIM: DDDD) Participation in Chardan Microbiome Summit
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit
4d Pharma PLC (AIM: DDDD) Parkinson’s trial receives FDA IND clearance
4D pharma announces FDA clearance of IND application for Live Biotherapeutics MRx0005 and MRx0029 for the treatment of Parkinson’s disease
4d Pharma PLC (AIM: DDDD) Restatement of Interim Results to June 30, 2021
4D pharma to Restate Unaudited Interim Financial Statements for the Six-Month Period Ended June 30, 2021 to Correct Accounting for Warrants
4d Pharma PLC (DDDD.L) Appoints John Doyle as Chief Financial Officer
Leeds, UK, January 4, 2022, – 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic Products (LBPs), a novel class of drug derived
4d Pharma PLC (DDDD.L) Phase 1/2 asthma study Part A results
4D pharma announces positive topline results from Part A of Phase I/II trial of MRx-4DP0004 for the treatment of asthma
4d Pharma PLC (DDDD.L) 4D pharma presents IBS Phase 2 microbiome analysis
4D pharma presents microbiome analyses from Phase II clinical trial of Blautix® for IBS-C and IBS-D at Gastro 2021
4d Pharma PLC (DDDD.L) Jefferies Next Generation IBD Therapeutics Summit
4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit
4d Pharma PLC (DDDD.L) 4D pharma presents two clinical posters for Live
Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021
OptiBiotix Health (OPTI.L) Extension of territories for Seed Health’s DS-01
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that its wholly-owned subsidiary, ProBiotix Health Ltd, has extended
4d Pharma PLC (DDDD.L) Two MRx0518 presentations accepted for ESMO 2021
4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021